Genentech is eliminating 474 employees, mostly based out of the company’s South San Francisco facilities, with the job cuts expected to be permanent.
GlaxoSmithKline started a trial to test an experimental rheumatoid arthritis drug on patients suffering from COVID-19 related pneumonia.
Recently published research in the journal Nature Genetics found significant insight into this question: Why does a patient with an autoimmune disease become a type 1 diabetic rather than have rheumatoid arthritis?
China’s Bio-Thera Solutions Ltd. won a regulatory approval for the company’s version of AbbVie Inc.’s blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world’s second-largest drug market.
AbbVie’s Rinvoq was approved by the FDA for treating adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
Gilead Sciences Inc. and Galapagos NV announced that the Marketing Authorization Application for filgotinib – an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis – was validated and is under evaluation by the European Medicines Agency.
Four months after reporting success in two rheumatoid arthritis trials with developmental partner Galapagos NV, Gilead Sciences Inc. is strengthening that partnership with a 10-year global research and development collaboration worth more than $5 billion. Gilead is also increasing the company’s stake in Galapagos.
Gilead Sciences announced that a path forward was established to submit a New Drug Application in 2019 for the investigational oral, selective JAK1 inhibitor filgotinib as a rheumatoid arthritis treatment.
Celltrion Healthcare presented new findings at the Annual European Congress of Rheumatology (EULAR 2019) from a two-part study investigating the pharmacokinetics, efficacy and overall safety of CT-P13 SC in patients with rheumatoid arthritis during the treatment period of one year.
Shares in Galapagos surged nearly 16 percent after the company reported positive results from several safety and efficacy trials of the Belgian drugmaker’s rheumatoid arthritis drug filgotinib.